Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Luveniq voclosporin: Phase IIb data

Top-line data from the double-blind, international Phase IIb AURA-LV trial in 265 patients with active lupus nephritis showed that twice-daily 23.7 mg oral voclosporin plus standard of care (SOC) mycophenolate mofetil (MMF) and oral corticosteroids met

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers